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INTRODUCTION
Colorectal cancer is known to involve multiple genetic and
epigenetic alterations (1). hMSH2 and hMLH1 are the two
main mismatch repair genes frequently mutated in hereditary
nonpolyposis colorectal cancer (HNPCC). Genomic instabil-
ity at short tandem repeats in the DNA, referred to as micro-
satellite instability (MSI), is the hallmark of mismatch repair-
deficient cancers (2-4). hMSH2 and hMLH1 are two princi-
pal proteins cooperative in DNA mismatch repair and hMLH1
acts as a downstream effector of hMSH2 (5).
However, the majority of sporadic colorectal cancers with
MSI do not harbor mutations in known mismatch repair
genes. Another potential mechanism underlying colorectal
cancer progression is epigenetic process marked by the pro-
moter region methylation shown in several tumor suppres-
sor genes. The promoter methylation in hMLH1 enables to
bring transcriptional silencing of hMLH1 (6-8).
Approximately 85-90% of HNPCC tumors show MSI,
whereas 15-20% of sporadic colorectal cancers do (9-11).
These mutator pathways have rarely been investigated in
younger-age-onset colorectal cancer patients not fulfilling the
clinical criteria of HNPCC. In this study, hMSH2 and hMLH1
mutations and other mutator phenotypes, i.e. MSI and
hMLH1 promoter methylation, were investigated to deter-




Twenty-one sporadic colorectal cancer patients younger than
30 yr were prospectively included from the Colorectal Cancer
Registry (Asan Medical Center, Seoul, Korea). Familial ade-
nomatous polyposis and HNPCC were excluded. The mean
age of the patients was 25 (19-30) yr and the male to female
ratio was 15:6. There were six cases of right-sided, two cases
of left-sided colon cancers, and 13 cases of rectal cancers. There
were four patients of stage I, two of stage II, ten of stage III,
and five of stage IV regarding AJCC tumor stage. DNA from
peripheral lymphocytes, tumors, and normal colonic tissues
was extracted using a standard method. Normal colonic tis-
sue was acquired at least 10 cm from the tumor. This study
was performed under the approval of the Institutional Review
Board. 
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The high-frequency microsatellite instability (MSI-H) phenotype, frequently identi-
fied in hereditary nonpolyposis colorectal cancer (HNPCC), also accounts for ap-
proximately 15% of sporadic colorectal cancers. Microsatellite instability (MSI)
occurs from the mutational inactivation of the DNA mismatch repair genes, i.e.
hMSH2 and hMLH1 in HNPCC, as well as from epigenetic inactivation of hMLH1
in sporadic colorectal tumors. The mutator pathway including microsatellite insta-
bility, hMLH1 promoter methylation, and hMSH2 and hMLH1 mutation patterns
were identified in 21 sporadic colorectal adenocarcinoma patients younger than
30 yr excluding HNPCC. More than half of tumors showed MSI, with five MSI-H
and six MSI-L (low-frequency microsatellite instability). Three of six MSI-H tumors
showed the hMLH1 promoter methylation and did not express the hMLH1 protein.
On the other hand, all MSI-L and all MSS (microsatellite stable) tumors expressed
both hMSH2 and hMLH1 proteins. Two novel mutations, i.e. a missense muta-
tion in hMLH1 and a splice-site alteration in hMSH2, were identified in two patients
respectively. Although mutator pathway was implicated in younger-age-onset colo-
rectal carcinogenesis, many tumors appeared to evolve from different genetic
events other than hMSH2 and hMLH1 mutations frequently identified in HNPCC.
Key Words : Colorectal Neoplasms; DNA Repair; Microsatellite Repeats; Methylation
Received : 27 December 2002
Accepted : 24 February 2003388 S.A. Roh, H.C. Kim, J.S. Kim, et al.
Detection of hMSH2 and hMLH1 
For PCR-SSCP analysis, previously defined oligonucleotide
primers were used (12). The reaction mixture consisted of
approximately 200 ng of template DNA in a volume of 50
L, 1 standard PCR buffer (Promega, Madison, WI), 1.5
mM Mg2+, 0.5 mM dNTPs, and 0.4 mM each specific oligo-
nucleotide primer. One-unit Taq polymerase was added per
reaction. Amplification was performed using the following
protocol: 94 for 4 min at the start, then 35 cycles of 94
for 1 min, respective annealing temperature for 1 min, 72
for 1min, and finally 72 for 10 min. 
PCR products were heated to 90 for 5 min and quenched
on ice. Electrophoresis was performed in 10% non-denatur-
ing polyacrylamide gel with an acrylamide: bisacrylamide
ratio of 30:0.8 containing 10% glycerol at 20 mA for 18 hr.
DNA bands of distinct mobility were detected by silver stain-
ing. DNA alterations identified on a PCR-SSCP were then
determined by direct sequencing. The PCR products were
sequenced on an ABI 377 DNA sequencer (Applied Biosys-
tems, Foster city, CA, U.S.A.).
Microsatellite Instability (MSI)
The MSI was identified on a PCR using primer sets of five
microsatellite loci according to the NCI recommendations
for colorectal cancer, i.e. BAT25, BAT26, D17S250, D5S346,
and D2S123 (13). Standard PCR was carried out in a 25  L
reaction mixture, containing 10 pmol of respective primers,
1.5 mmol/L MgCl2, 0.2 mmol/L each of dNTP, and 0.5 units
of Taq DNA polymerase (Promega, Madison, WI). Consec-
utive PCR consisted of an initial denaturation step at 94
for 4 min, followed by 34 cycles of 94 for 30 sec, 45-60
for 30 sec, and 72 for 30 sec, and a final extension step at
72 for 7 min. Denaturation of PCR products, gel eletropho-
resis, and silver staining were performed as previously described
(14). Tumor DNA showing alleles that were not present in
the corresponding normal DNA were classified as MSI posi-
tive. Tumors were defined as MSI-H (high-frequency MSI)
when MSI was identified in at least two loci, as MSI-L (low-
frequency MSI) in one locus, and as MSS (microsatellite sta-
ble) in no locus.
Methylation-specific PCR (MSP)
The DNA methylation pattern in the CpG islands of the
hMLH1 promoter region was determined by sodium bisulfite
modification and subsequent MSP as described previously (6).
Primer sequences of hMLH1 for unmethylated DNA were
5 -TTT TGA TGT AGA TGT TTT ATT AGG GTT GT-
3 (sense) and 5 -ACC ACC TCA TCA TAA CTA CCC
ACA-3 (antisense), and for methylated DNA were 5 -ACG
TAG ACG TTT TAT TAG GGT CGC-3 (sense) and 5 -
CCT CAT CGT AAC TAC CCG CG-3 (antisense). The
PCR mixture contained 10 PCR buffer (16.6 mM ammo-
nium sulfate, 67 mM Tris (pH 8.8), 6.7 mM MgCl2, and 10
mM 2-mercaptoethanol), dNTPs (each 1.25 mM), primers
(300 ng each per reaction), and bisulfite-modified DNA (50
ng) in a final volume of 50  L. The reaction was performed
using hot start at 95 for 5 min followed by addition of 1.25
units Taq polymerase. Amplification was carried out using a
PCR Express Thermal Cycler (Hybaid, Middlesex, U.K.) for
35 cycles (30 sec at 95 , 30 sec at 53 , then 30 sec at 72
), followed by final 4 min extension at 72 The colon
cancer cell line SW48, known as completely methylated at
the hMLH1 promoter region, was used as positive control. Ten
L of each PCR reaction product were directly loaded onto
nondenaturing 6% polyacrylamide gels. Gels were stained
with ethidium bromide and visualized under UV transillu-
minator.
Any indeterminate results were repeatedly verified for MSI
and methylation analyses.
Immunohistochemistry
Slides with 5- m sections were deparaffinized in xylene,
rehydrated in graded alcohols, and washed in ddH2O. Endo-
geneous peroxidase activity was blocked by incubation with
3% H2O2. Antigen retrieval was accomplished in 10 mM
citrate buffer (pH 6.0) by boiling in a microwave for 15 min.
After treatment with 10% normal goat serum for 10 min to
block nonspecific protein binding, mouse monoclonal anti-
body against hMLH1 (PharMingen, San Diego, CA) and
hMSH2 (PharMingen, San Diego, CA) were applied. Anti-
gen-antibody reactions were visualized using the avidin-bio-
tinylated horseradish peroxidase complex (DAKO LSAB kit,
Los Angeles, CA) and diaminobezidine as chromogen. Slides
were counterstained with hematoxylin. Normal tissues adja-
cent to respective tumor was used as an internal positive con-
trol. A distinct nuclear staining more than 10% of all nuclei
was interpreted as positive staining for hMSH2 and hMLH1.
RESULTS
Patterns of hMSH2 and hMLH1 mutations
All coding exons and exon-intron borders of hMSH2 and
hMLH1 genes were examined using genomic DNA samples.
Two different novel mutations were found in two patients
(Fig. 1). One missense mutation in the hMLH1 exon 10 (845
C G, A282G) was identified. The other mutation was splice-
site alteration in the hMSH2 intron 10 (1661 6, T C).
MSI and MSP
There were five cases (23.8%) of MSI-H, six cases (28.6%)
of MSI-L, and 10 cases (47.6%) of MSS in 21 colorectal ade-Mutator Pathway in Younger-age-onset Colorectal Cancer 389
nocarcinomas (Fig. 2). When MSI-H tumors were compared
with MSI-L and MSS tumors together, they did not differ in
sex, tumor location, histologic differentiation, or cancer stage
(Table 1). Three of MSI-H tumors showed hMLH1 promot-
er methylation, whereas all MSI-L tumor and MSS tumors
did not. MSI-H tumors were significantly associated with
hMLH1 promoter methylation (p<0.001, Fisher' s exact test).
hMSH2 promoter methylation was not identified in any of
the tumors.
Fig. 2. Microsatellite patterns and hMLH1 promoter methylation in
patients with MSI-H using five markers. MSI (+) cases: BAT25
(all); BAT26 (9, 14, 16, 19)'D2S123 (9, 19); D5S346 (9, 16, 19);
D17S250 (1, 14, 16). Paired samples of normal (left) and tumor
(right) shown at each MSI locus; U, unmethylated DNA; M, methy-
lated DNA. 
Fig. 1. hMLH1 and hMSH2 mutations in the younger age-onset spo-
radic colorectal cancer. A missense mutation in exon 10 (A282G,
845 C G) of hMLH1 in case 5 (left) and a splice-site alteration in
intron 10 (1661+6, T C) of hMSH2 in case 11 (right).
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U   M U   M U   M U   M U   M
1 RC MUC - H (2) M U - +
2R M D - S U U + +
3 RC MUC - L U U + +
4 RC MUC - S U U + +
5R M D + S U  U + +
6R C P D - S U U + +
7L C M D - S U U + +
8R M D - L U U + +
9 R MD - H (4) U U + +
10 R MD - S U U + +
11 R MD + S U U + +
12 R MD - S U U + +
13 R MUC - L U U + +
14 RC MD - H (3) M U - +
15 R MD - L U U + +
16 RC WD - H (4) U U + -
17 R MD - S U U + +
18 R WD - L U U + +
19 R MD - H (4) M U -  +
20 R MUC - L U U + +
21 LC SRC - S U U + +
*RC, right colon (cecum - transverse colon); LC, left colon (descending-sigmoid colon); R, rectum.  WD, well differentiated; MD, moderately differenti-
ated; PD, poorly differentiated; MUC, mucinous; SRC, signet ring cell.  H, MSI-H; L, MSI-L; number of unstable markers in the parenthesis.  U,
unmethylated; M, methylated.  IHC, Immunohistochemical staining; +, normal nuclear expression;   , absent nuclear expression.
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Immunohistochemistry
Three tumors of MSI-H with hMLH1 promoter methyla-
tion did not express hMLH1 protein and one MSI-H tumor
without promoter methylation expressed both hMSH2 and
hMLH1 proteins. The other MSI-H tumor did not express
hMSH2 with profuse expression of hMLH1. All MSI-L and
MSS tumors showed profuse expression of both hMSH2 and
hMLH1 proteins. In patients younger than 20 y, all tumors
showed both hMSH2 and hMLH1 protein expression.
DISCUSSION
MSI-H was identified in less than one quarter of younger-
age-onset sporadic colorectal carcinoma in our study. MSI-H
cancers constitute 10-15% of sporadic colorectal cancers and
virtually all cancers of the HNPCC (15). HNPCC and spo-
radic MSI-H cancers came to be regarded as familial and spo-
radic counterparts of the same mutator pathway, respective-
ly, in their tumorigenesis (15). Both the frequency and extent
of de novo methylation has been shown to increase strikingly
in the colon cancer with MSI-H. A significantly lower fre-
quency of hMLH1 promoter methylation has been identified
in HNPCC than in MSI-H sporadic colorectal cancers, show-
ing none in 30 HNPCC cancers with MSI-H and 80% in 40
sporadic colorectal cancers with MSI-H (16). In sporadic colo-
rectal cancers with MSI-H, hMLH1 promoter methylation
is extremely frequent and often accompanied by down-reg-
ulation of hMLH1 gene expression (17).
In our study, more than half of MSI-H cancers included
hMLH1 promoter methylation without hMLH1 protein
expression. Many investigations reported that a large portion
of the MSI-H in sporadic colorectal cancer occurred from
hMLH1 promoter methylation (1, 6). The immunohistochem-
istry of hMSH2 and hMLH1 has been known to predict MSI-
H with great sensitivity (92.3%) and specificity (up to 100%)
(18, 19). All tumors without either hMSH2 or hMLH1 ex-
pression were MSI-H in our study. On the other hand, all
MSI-L and MSS tumors showed both hMSH2 and hMLH1
protein expression. One MSI-H cancer without hMLH1 pro-
moter methylation showed hMSH2 and hMLH1 protein ex-
pression in our study. Several investigations proposed that
some tumors with MSI-H showing normal expressions of
hMSH2 and hMLH1 possibly occur from presence of the wild
type allele or hMSH6 mutation (17, 20). The promoter methy-
lation has been known to correlate with the CpG island methy-
lation phenotype (CIMP) in subsets of cancer specific genes,
i.e. P16INK4A and THBS1 in sporadic colorectal carcinomas (2).
Approximately 70% of HNPCC patients with MSI tumors
have been found to have germline mutations in one of the
mismatch repair genes (18). Although some of the MSI pos-
itive sporadic colorectal cancers demonstrated mutations in
one of the mismatch repair genes (21), the majority of these
cancers had no identifiable mutation (22, 23). Two germline
mutations were identified in two patients of our study (9.5%).
The other study including colorectal cancer patients younger
than 30 yr showed hMSH2 or hMLH1 mutation in two of
14 patients with no family history of any cancers (24). How-
ever, missed mutations, i.e. large deletions with genomic rear-
rangement, cannot be excluded with PCR-SSCP analysis. The
efficiency of PCR-SSCP in detection of single-base substitu-
tion is known to be more than 95% in fragments of less than
300-350 bp (25). One missense mutation in hMLH1 and the
other splice-site alteration in hMSH2 did not alter hMSH2
and hMLH1 protein expression in our study. As these alter-
ations may frequently show functional significance and im-
munologic reactivity to poorly functional proteins (18, 26),
their pathogenic significance cannot be excluded. Further-
more, these alterations have not been reported in healthy indi-
viduals (ICG-HNPCC database 2003, http://www.nfdht.nl/)
and our missense mutation included non-conservative amino
acid change from non-polar alanine to polar glycine. MSI can-
cers have been reported to have different characteristics in
terms of proximal colonic location, mucinous and undiffer-
entiated histology (13). In our study, these clinicopatholog-
ic features did not differ by MSI status in a multiple regres-
sion analysis, probably due to the limited sample size.
The mutator pathway other than hMSH2 and hMLH1 mu-
tations appeared to be implicated in many younger-age-onset
colorectal cancers. It can be included in the category of a vari-
ant form of sporadic colorectal cancer rather than that of
HNPCC regarding genetic and epigenetic phenotypes. 
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